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NSAIDs-hypersensitivity often 
induces a blended reaction pattern 
involving multiple organs
Inmaculada Doña  1,2, Esther Barrionuevo1,2, María Salas1,2, José Julio Laguna3,4, 
José Agúndez5,6, Elena García-Martín5,6, Gádor Bogas  1, James Richard Perkins7, 
José Antonio Cornejo-García2,7 & María José Torres1,2
Non-steroidal anti-inflammatory drugs (NSAIDs)-induced hypersensitivity reactions are classified 
by the European Network on Drug Allergy (ENDA) as either cross-reactive or selective. The former 
is the most frequent type and includes patients with exclusively respiratory symptoms (NSAIDs-
exacerbated respiratory disease, NERD) or exclusively cutaneous symptoms: NSAIDs-induced urticaria/
angioedema (NIUA); and NSAIDs-exacerbated cutaneous disease (NECD). However, although not 
reflected in the current classification scheme (ENDA), in clinical practice a combination of both skin 
and respiratory symptoms or even other organs such as gastrointestinal tract symptoms (mixed or 
blended reactions) is frequently observed. This entity has not been sufficiently characterised. Our 
aim was to clinically characterize blended reactions to NSAIDs, comparing their clinical features with 
NERD and NIUA. We evaluated patients with symptoms suggestive of hypersensitivity to NSAIDs 
who attended the Allergy Unit of the Regional University Hospital of Malaga (Malaga, Spain) between 
2008 and 2015. We included 880 patients confirmed as cross-reactive based on clinical history, positive 
nasal provocation test with lysine acetylsalicylate (NPT-LASA), and/or positive drug provocation test 
(DPT) with acetylsalicylic acid (ASA), who were classified as blended (261; 29.6%), NERD (108; 12.3%) 
or NIUA (511; 58.1%). We compared symptoms, drugs, underlying diseases and diagnostic methods 
within and between groups. Among blended patients the most common sub-group comprised those 
developing urticaria/angioedema plus rhinitis/asthma (n = 138), who had a higher percentage of 
underlying rhinitis (p < 0.0001) and asthma (p < 0.0001) than NIUA patients, showing similarities to 
NERD. These differences were not found in the sub-group of blended patients who developed such 
respiratory symptoms as glottis oedema; these were more similar to NIUA. The percentage of positive 
NPT-LASA was similar for blended (77%) and NERD groups (78.7%). We conclude that blended reactions 
are hypersensitivity reactions to NSAIDs affecting at least two organs. In addition to classical skin 
and respiratory involvement, in our population a number of patients also develop gastrointestinal 
symptoms. Given the high rate of positive responses to NPT-LASA in NERD as well as blended reactions, 
we suggest that all patients reporting respiratory symptoms, regardless of whether they have other 
associated symptoms, should be initially evaluated using NPT-LASA, which poses less risk than DPT.
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most frequent triggers of drug hypersensitivity 
reactions (DHRs)1–4. Several classifications have been proposed5–8, including a recently published and heavily 
cited publication from the European Network on Drug Allergy (ENDA) group from the European Academy 
of Allergy and Clinical Immunology (EAACI)9. They classify hypersensitivity reactions to NSAIDs according 
to the clinical symptoms induced, the number of NSAIDs involved, and the presence or absence of underlying 
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diseases such as: (1) NSAIDs-exacerbated respiratory disease (NERD); (2) NSAIDs-exacerbated cutaneous 
disease (NECD); (3) NSAIDs-induced urticaria/angioedema (NIUA); (4) single-NSAID-induced urticaria/
angioedema and anaphylaxis (SNIUAA), or (5) single-NSAID-induced delayed hypersensitivity reactions 
(SNIDHR). The first three groups are not thought to be immunologically-mediated, rather they are due to the 
inhibition of the cyclooxygenase (COX)-1 enzyme, with patients reacting to NSAIDs from chemically unrelated 
groups (cross-reactive hypersensitivity). The last two groups (SNIUAA and SNIDHR) encompass immunologi-
cally mediated reactions induced by a single NSAID/NSAIDs group (selective hypersensitivity)9.
Cross-reactive hypersensitivity to NSAIDs is the most frequent type of reaction for all age groups10,11. 
Classically, NERD is characterized by exacerbations of asthma and/or rhinitis after NSAIDs intake in patients with 
underlying chronic respiratory disease12,13. NIUA, the most frequent clinical entity10, is characterised by the acute 
appearance of cutaneous symptoms in otherwise healthy individuals, i.e. without chronic spontaneous urticaria 
(CSU)9. NECD occurs in patients with a history of CSU who develop an exacerbation of this pathology after taking 
NSAIDs. SNIUAA and SNIDHR are characterized by immediate or non-immediate reactions to a given NSAID or 
several NSAIDs from the same chemical group but tolerance to other non-chemically related NSAIDs14,15.
Although this classification is widely accepted and the groups outlined above represent well-defined pheno-
types, not all clinical patterns fit neatly within a single category5–8,10,16. Patients with cross-reactive hypersensitivity 
to multiple NSAIDs may simultaneously develop a combination of skin and respiratory symptoms independently 
of the presence of underlying CSU, asthma or rhinosinusitis. For example, they often experience angioedema and/
or urticaria alongside rhinoconjunctivitis and/or bronchial asthma after NSAIDs intake5–8,10,16,17. Such reactions 
involving at least two different organs were originally labelled as blended6, and in most cases the skin and airways 
are affected, although other organs may also be involved, such as the gastrointestinal tract5–8,10,16,17. However, in 
the ENDA classification, respiratory and cutaneous reactions are mutually exclusive and there is no single cate-
gory in which to classify patients who have multiple organs affected after NSAIDs intake. Blended reactions have 
been estimated to account for more than a quarter of all reactions induced by cross-reactive hypersensitivity to 
NSAIDs in adults10 and up to 40% in children17.
To the best of our knowledge, no focused studies have been performed to evaluate the clinical characteristics 
and optimal diagnostic approaches for blended reactions, and it is still unclear whether these reactions are part of 
the NERD-NIUA spectrum, or a different entity altogether. In our clinical experience and in the literature5–8,10,16,17, 
blended reactions are almost never found in patients with NECD, as a result we excluded them from this study.
Here we have performed an in-depth analysis of patients suffering from blended reactions to NSAIDs, pre-
senting some combination of cutaneous, respiratory and/or gastrointestinal symptoms. We have compared the 
clinical and demographic characteristics of these patients to those with exclusively respiratory (NERD) or cuta-
neous (NIUA) symptoms.
Methods
Patients. We evaluated patients aged 14–80 years old with symptoms suggestive of DHRs to one or more 
NSAIDs who attended the Allergy Unit of the Regional University Hospital of Malaga (Malaga, Spain) between 
2008 and 2015. Of these, we included patients with a confirmed diagnosis of cross-reactive hypersensitivity to 
NSAIDs, defined by meeting at least one of the following criteria: (i) having experienced 3 or more episodes of 
cutaneous (urticaria and/or angioedema), respiratory (rhinitis, asthma and/or glottis oedema) and/or gastro-
intestinal symptoms (periumbilical colic pain, vomiting and/or diarrhoea) after the intake of at least 3 distinct 
NSAIDs from different chemical groups including a strong COX-1 inhibitor (acetylsalicylic acid (ASA) and/or 
indomethacin)18; (ii) having experienced less than 3 episodes of respiratory symptoms, with or without other 
organs involved after the intake of 2 different or only one NSAID, and giving a positive nasal provocation test with 
lysine acetyl salicylate (NPT-LASA); (iii) having had less than 3 episodes of cutaneous symptoms, with or without 
respiratory and/or gastrointestinal symptoms induced by less than 3 different NSAIDs and giving a positive NPT-
LASA or drug provocation test (DPT) to ASA (Fig. 1).
Exclusion criteria included the following: patients with delayed DHRs such as fixed drug eruption, erythema 
multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis complex or acute generalised exanthematic 
pustulosis; pregnant or breastfeeding patients; patients taking beta-blockers or ACE inhibitors or with contraindi-
cations for epinephrine administration; patients with acute infections and/or underlying cardiac, hepatic or renal 
diseases that contraindicated DPT; patients with CSU that was exacerbated by NSAIDs (NECD); patients with 
psychosomatic disorders; patients reporting throat tightness not associated with dysphonia, difficulty breathing 
and swallowing and glottis oedema was not observed by fiberscope; and patients reporting gastrointestinal symp-
toms such as epigastric burning and hemorrhage related to alterations in the gastroduodenal mucosa secondary 
to the pharmacology action of NSAIDs.
The study was conducted according to the principles of the Declaration of Helsinki and approved by the 
Provincial Investigational Ethics Committee of Malaga. All participants were informed orally about the study 
and signed the corresponding informed consent. In the case of participants under the age of 18 years, informed 
consent was obtained from a parent and/or legal guardian.
Patient classification. Patients were classified according to the symptoms experienced after ASA or other 
strong COX-1 inhibitor as: (i) NERD if they had respiratory symptoms (rhinitis and/or asthma); (ii) NIUA if they 
had skin symptoms (urticaria and/or angioedema); and (iii) blended if they had a combination of skin, respira-
tory and/or gastrointestinal symptoms (urticaria; angioedema; rhinitis; asthma; throat tightness associated with 
dysphonia, difficulty breathing and swallowing; periumbilical colic pain; vomiting and/or diarrhoea). Glottis 
oedema was observed using a fibroscope in patients reporting throat tightness associated with dysphonia, diffi-
culty breathing and swallowing.
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Clinical history. Patients were questioned about the symptoms that appeared after NSAIDs intake, the time 
interval between drug intake and reaction onset, the number of episodes, the number of NSAIDs involved in the 
episodes, underlying nasal and bronchial symptoms (sneezing, itching, watery nose, nasal blockage, difficulty 
breathing, cough and wheezing), food allergy (urticaria, angioedema, oral allergy syndrome, anaphylaxis and 
shock), and CSU.
Atopic status. Atopic status was assessed by skin prick test (SPT) using a panel of 20 common inhalant aller-
gens, including pollens, house dust mites, moulds and animal dander, and 27 common food allergens including 
animal, fruit and vegetable allergens (ALK, Madrid, Spain). Histamine hydrochloride (10 mg/ml) and phenolated 
glycerol saline were used as positive and negative controls, respectively. Patients were requested to stop taking 
any antihistamine medication at least 8 days before undertaking SPT. A positive SPT response was defined as a 
wheal diameter of 3 mm or larger to at least one of these allergens and any patient producing such a wheal was 
considered atopic.
Nasal and oral drug provocation testing. NPT-LASA was carried out as described in patients reporting 
respiratory symptoms regardless of the other organs involved19. Results were considered positive if an increase 
≥30% in the total nasal symptoms and a decrease ≥30% in the total volume of both nasal cavities from 2 to 6 cm 
(vol 2–6 cm), measured by acoustic rhinometry, was observed.
Oral drug provocation testing (DPT) was performed in NIUA patients, and in blended and NERD patients 
who gave negative NPT-LASA results. DPT was performed in a single-blind manner as reported10. Briefly, pla-
cebo capsules were given at different times on the 1st day; three doses of ASA were administered orally at intervals 
of 90 min (10, 50 and 50 mg) on the 2nd day; and, if negative, three doses of ASA (125, 125 and 250 mg) were 
administered on the 3rd day. If cutaneous and/or respiratory symptoms or changes in vital signs (rhythm altera-
tions, decrease in FEV1 or hypotension) appeared, the procedure was stopped and symptoms were evaluated and 
treated. If no symptoms appeared during drug administration, the therapeutic dose of ASA was achieved and this 
was followed by a 2 day/8 h course at maximum dose, after a gap of 24 h. ASA and placebo were given in opaque 
capsules prepared by the hospital pharmacy service. Other medications were withheld before testing, according 
to international guidelines20.
Statistical analysis. Descriptive statistics (frequency, mean, median and range) were used to present 
results, as indicated. Chi-square analysis was used to test differences for nominal variables, and the Fisher test 
was used when criteria for using the chi-square test was not met. For quantitative variables, non-parametric 
Mann-Whitney and Kruskal-Wallis tests were used. All reported p-values represented two-tailed tests, with val-
ues <0.05 considered significant.
Results
A total of 2848 patients with symptoms suggestive of NSAIDs hypersensitivity were evaluated in the Allergy Unit 
of the Regional University Hospital of Malaga between 2008 and 2015. Of these, diagnosis could not be achieved 
for 1662 patients (1230 could not undergo DPT to ASA due to age or comorbidities, 376 refused to perform the 
study, and 56 were excluded due to pregnancy), and 267 individuals were diagnosed with selective reactions. This 
Figure 1. Algorithm for diagnosing patients with a history of hypersensitivity reaction after NSAIDs intake.
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left a total of 919 patients (32.3%) diagnosed as having cross-reactive hypersensitivity. Of these, only 4.2% were 
classified as NECD, and were therefore not further considered.
Of the 880 patients finally included, 511 (55.1%) were diagnosed with NIUA, 261 (28.4%) classified as suffer-
ing blended reactions and 108 (11.7%) diagnosed with NERD. A total of 560 patients (63.6%) were female and the 
median age at diagnosis was 38 years (IQR: 28–50). Five hundred and eighty-one (66%) patients were atopic, the 
most common allergens being Dermatophagoides pteronyssinuss (359; 40.8%), Olea europaea (276; 31.4%), and 
Lolium perenne (192; 21.8%). A total of 420 (47.7%) had underlying rhinitis; 291 (33.1%) had asthma; 66 (7.5%) 
had nasosinusal polyposis and 15 (1.7%) had food allergy (4 to nuts, 9 to shellfish and 4 to melon).
A comparison of the demographic and clinical data between the different groups is shown in Table 1. We 
found that the proportions of patients having underlying rhinitis and asthma were higher in the blended group 
compared to NIUA (p = 0.0002 and p < 0.0001, respectively), but lower than NERD (p > 0.05 and p < 0.0001, 
respectively). In addition, polyposis was also less frequent in blended than NERD but more frequent than NIUA 
(p < 0.0001 for both comparisons). The proportion of atopic patients was similar when comparing blended with 
NIUA, but higher when comparing blended with NERD (p = 0.002) (Table 1 and Supplementary Table). No 
NIUA patient had nasosinusal polyposis and no patient diagnosed with NERD or as having blended reactions 
had food allergy.
Analyses of patient reactions according to clinical records are shown in Tables 2 and 3. Patients reported a 
median of 3 episodes after NSAIDs intake, and a median of 2 different NSAIDs were involved, with no differences 
between groups. The median onset time interval after NSAIDs intake was 45 minutes when considering patients 
from all groups (IQR: 20–120). When comparing between groups, blended reactions and NERD showed similar 
onset times (median: 30 minutes; IQR: 20–90, and median: 30; IQR: 15–120, respectively). However, this interval 
was shorter in patients with blended reactions compared to NIUA (median: 60; IQR: 30–120) (p = 0.0003) (Table 2).
Considering all groups together, 545 patients (61.9%) reported reactions to ibuprofen; 343 to dipyrone (39%); 
333 to ASA (37.8%); 185 to diclofenac (21%); 208 to paracetamol (23.6%); 70 to dexketoprofen (7.9%); 60 to 
naproxen (6.8%); 28 to piroxicam (3.2%); 18 to lysine clonixinate (2%); 10 to indomethacine (1.1%), 9 to a selec-
tive COX-2 inhibitor (1%) and 5 to meloxicam (0.6%).
The percentage of reactions induced by dipyrone was higher in blended reactions compared to NERD (41.4% 
and 27.8%, p = 0.004). It was also higher for NIUA then NERD (40% and 27.8%, p = 0.03), as was paracetamol 
(27.5% vs 13.9%, p = 0.02). No significant differences found for other drugs (Table 2).
Analysis of the clinical symptoms in the blended reactions group shows several general patterns (Table 3). 
Patients can be classified into 4 sub-groups: patients developing skin symptoms (urticaria/angioedema) and 
rhinitis/asthma (Sub-group I); patients developing skin symptoms (urticaria/angioedema) and glottis oedema 
(Sub-group II); patients developing skin symptoms (urticaria/angioedema), rhinitis/asthma and glottis oedema 
(Sub-group III); and patients experiencing a combination of gastrointestinal symptoms (abdominal pain, 
Blended 
n = 261
NERD 
n = 108
NIUA 
n = 511
p-value Blended vs 
NERD vs NIUA
p-value Blended 
vs NERD
p-value Blended 
vs NIUA
p-value NERD 
vs NIUA
Age median (IQR) 37 (29–48) 39 (30–48.5)
38 
(28–50.7) NS NS NS NS
Gender (female), n (%) 176 (67.4) 73 (67.6) 296 (58) 0.03 NS 0.01 0.01
Underlying rhinitis, n (%) 158 (60.5) 77 (71.3) 185 (36.2) <0.0001 NS 0.0002 <0.0001
Underlying asthma, n (%) 123 (47.1) 70 (64.8) 98 (19.2) <0.0001 <0.0001 <0.0001 <0.0001
Nasosinusal polyposis, n (%) 24 (9.2) 42 (38.9) 0 <0.0001 <0.0001 <0.0001 <0.0001
Food allergy, n (%) 0 0 15 (3) 0.004 NS 0.005 NS
Atopy, n (%) 187 (71.6) 59 (54.6) 335 (65.5) NS 0.002 NS NS
Positive to at least one inhalant allergen, n (%) 181 (69.3) 59 (54.6) 328 (64.2) NS NS NS NS
Lolium; 91 (34.9) 19 (17.6) 82 (16) 0.001 0.03 0.0002 NS
Cupressus; 28 (10.7) 1 (0.9) 48 (9.4) 0.014 0.002 NS 0.005
Olea; 98 (37.5) 19 (17.6) 159 (31.1) 0.004 NS NS 0.02
Parietaria; 19 (7.3) 9 (8.3) 30 (5.9) NS NS NS NS
Salsola; 22 (8.4) 2 (1.8) 40 (7.8) NS NS NS NS
D. pteronyssinuss; 108 (41.4) 32 (29.6) 219 (42.8) NS NS NS NS
Alternaria; 46 (17.6) 6 (5.5) 37 (7.2) 0.016 0.02 0.008 NS
Dog dander; 76 (29.1) 12 (11.1) 73 (14.3) 0.003 0.005 0.002 NS
Cat dander; 67 (25.7) 13 (12) 88 (17.2) NS 0.03 NS NS
Positive to at least one food allergen, n (%) 81 (31) 32 (29.6) 83 (16.2) NS NS NS 0.02
Pru p 3 28 (10.7) 0 26 (5.1) 0.0001 0.0003 NS 0.01
Apple 24 (9.2) 0 10 (3.8) <0.0001 0.001 NS NS
Peanut 49 (18.7) 15 (13.9) 14 (2.7) 0.03 NS 0.04 NS
Walzetnut 49 (18.7) 15 (13.9) 15 (2.9) 0.03 NS 0.04 NS
Melon 23 (8.8) 0 22 (4.3) 0.0009 0.001 NS 0.02
Shrimp 29 (11.1) 10 (9.2) 14 (2.7) 0.01 NS 0.04 0.04
Table 1. Demographic and clinical data of study participants. IQR: interquartile range; NS: Not significant.
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diarrhoea, nausea, vomiting) with skin symptoms (urticaria/angioedema) and/or rhinitis/asthma (Sub-group 
IV) (Table 3). Sub-group I was the most frequent (n = 138; 52.9%), followed by Sub-group II (n = 100; 38.3%), 
Sub-group III (n = 15; 5.7%) and Sub-group IV (n = 8; 3.1%). The proportion of underlying rhinitis, asthma, 
nasosinusal polyposis and atopy in the 4 Sub-groups of patients developing blended reactions is compared to 
NERD and NIUA in Fig. 2. Sub-group I contained a similar proportion of patients with underlying rhinitis (98; 
71.01%) and asthma (85; 61.59%) to NERD patients (rhinitis: 77; 71.3%; asthma: 70; 64.8%), but different to 
NIUA (rhinitis: 185; 36.2%; asthma: 98; 19.2%) (p < 0.0001 for both comparisons). In Sub-groups II, III and 
IV, the proportions of patients with underlying rhinitis (Sub-group II: 50; 50%; Sub-group III: 7; 46.66%; and 
Blended 
n = 261
NERD 
n = 108 NIUA n = 511
p-value Blended vs 
NERD vs NIUA
p-value Blended 
vs NERD
p-value Blended 
vs NIUA
p-value NERD 
vs NIUA
Time interval drug-reaction, median (IQR) (min) 30 (20–90) 30 (15–120) 60 (30–120) 0.001 NS 0.0003 NS
Drugs involved n, (%)
ASA 105 (39.9) 34 (31.5) 194 (38) NS NS NS NS
Indomethacin 3 (1.1) — 7 (1.4) NS NS NS NS
Diclofenac 59 (22.6) 20 (18.5) 106 (20.7) NS NS NS NS
Ibuprofen 142 (54.4) 66 (61.1) 337 (65.7) NS NS NS NS
Naproxen 18 (6.9) 6 (5.5) 36 (34.8) NS NS NS NS
Dexketoprofen 18 (6.9) 8 (7.4) 44 (8.5) NS NS NS NS
Dipyrone 108 (41.4) 30 (27.8) 205 (40) 0.004 0.004 NS 0.03
Piroxicam 9 (3.4) 3 (2.8) 16 (3.1) NS NS NS NS
Paracetamol 52 (19.9) 15 (13.9) 141 (27.5) 0.003 NS NS 0.002
Meloxicam 2 (0.8) 1 (0.9) 2 (0.4) NS NS NS NS
Lysine clonixinate 7 (2.7) 2 (1.8) 9 (1.8) NS NS NS NS
Selective COX-2 3 (1.1) — 6 (1.2) NS NS NS NS
Number of episodes, median (IQR) 3 (2–4) 3 (2–4) 3 (3–4) NS NS NS NS
Number of drugs involved, median (IQR) 3 (1.25–3) 2 (1–3) 2 (2–3) NS NS NS NS
Time interval between the last reactions and 
diagnosis, median (IQR) 7 (3–24) 7 (5.5–8.5) 5 (2–23) NS NS NS NS
Table 2. Clinical characteristics of the reactions based on data reported by patients. IQR: interquartile range; 
NS: Non significant.
Group Symptoms n (%)
Blended n = 261
Skin + Rhinitis/Asthma (Sub-group I) n = 138
AE + Asthma 48 (18.4)
Urticaria + Asthma 48 (18.4)
AE + Rhinitis 17 (6.5)
Urticaria + AE + Asthma 8 (3.1)
AE + Rhinitis + Asthma 7 (2.7)
Urticaria + AE + Rhinitis + Asthma 5 (1.9)
Urticaria + Rhinitis + Asthma 3 (1.1)
Urticaria + AE + Rhinitis 2 (0.8)
Skin + GE (Sub-group II) n = 100
AE + GE 59 (22.6)
Urticaria + AE + GE 24 (9.2)
Urticaria + GE 17 (6.5)
Skin + Rhinitis/Asthma + GE (Sub-group III) n = 15
Urticaria + Asthma + GE 5 (1.9)
AE + Rhinitis + GE 4 (1.5)
AE + Asthma + GE 4 (1.5)
Urticaria + Rhinitis + Ashtma + GE 2 (0.8)
GI + Skin/Rhinitis/Asthma/GE (Sub-group IV) n = 8
GI + Rhinitis + Asthma 4 (1.5)
GI + AE + Asthma 4 (1.5)
NERD n = 108
Rhinitis 20 (18.5)
Asthma 64 (59.2)
Rhinitis + Asthma 24 (22.2)
NIUA n = 511
Urticaria 89 (17.4)
AE 124 (24.3)
Urticaria + Angioedema 298 (58.3)
Table 3. Symptoms induced by NSAIDs according to patient report. AE: Angioedema; GE: Glottis oedema; GI: 
Gastrointestinal symptoms.
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Sub-group IV: 3; 37.5%), asthma (Sub-group II: 31; 31%; Sub-group III: 4; 26.66%; and Sub-group IV: 3; 37.5%) 
and nasosinusal polyposis (zero for Sub-groups II, III and IV) were lower than in NERD, whereas underlying 
rhinitis and asthma showed similar proportions to NIUA. However, these differences were only significant for 
rhinitis and asthma between Sub-group II and NERD (p = 0.03 and p = 0.005, respectively). The percentage of 
atopy was similar for all subgroups of patients developing blended reactions, being similar to that of NIUA and 
higher than NERD, although significant differences were only found for Sub-group I, when compared to both 
NERD and NIUA (p = 0.001 and p = 0.02, respectively).
When considering the chronological appearance of clinical symptoms after NSAIDs intake by blended reac-
tion patients, we found that 197 (75.5%) developed cutaneous symptoms first, followed by respiratory manifes-
tations; 59 (22.6%) developed respiratory symptoms followed by skin and/or gastrointestinal symptoms, and 5 
(1.9%) developed gastrointestinal symptoms followed by respiratory and/or skin symptoms.
The mean time interval between last reaction and diagnosis was 6 months (IQR: 2.5–24), with no statistically 
significant differences between groups.
The proportion of patients that could be diagnosed using only clinical history varied between groups 
(p < 0.0001). For NIUA it could be used for the diagnosis of 340 patients (66.5% of the total NIUA patients), 
for NERD it could be used for 22 (20.4% of the total NERD patients) and for blended it was 41 (15.7% of the 
total blended patients). In 286 patients (32.5%) the diagnosis was confirmed by NPT-LASA: 85 from the total of 
NERD patients (78.7%) and 201 from the total of blended patients (77%) (Table 4). Considering the 4 sub-groups 
of patients with blended reactions mentioned above, no statistically significant differences were found in terms 
of the percentage of patients giving positive NPT-LASA: 84.8% for Sub-group I, 66% for Sub-group II, 80% for 
Sub-group III, and 75% for Sub-group IV. None of the patients who underwent NPT-LASA suffered bronchial 
symptoms or a significant fall in FEV1 upon administration.
The proportion of patients that were diagnosed using DPT also varied between groups (p < 0.0001). For NIUA 
it could be used for the diagnosis of 172 patients (33.6% of the total NIUA patients), for NERD it could be used 
for 3 (2.7% of the total NERD patients), and for blended it was 19 (7.3% of the total blended patients). Patients 
reacted to a median cumulative ASA dose of 250 mg (IQR: 100–500) with a median time interval of 75 minutes 
(IQR: 30–120) after the last administered dose. Although no statistical differences were found, NERD patients 
tended to react to a lower ASA dose (median: 75 mg; IQR: 46.25–200) compared to NIUA (median: 300 mg; IQR: 
100–500) and blended reaction patients (median: 250 mg; IQR: 113.75–500) (Table 5). Patients with positive DPT 
responses to ASA experienced similar symptoms to those recorded in their clinical history, however they were 
generally milder, disappearing within 1–2 h after taking corticosteroid and antihistamine drugs and, if bronchial 
symptoms occurred, inhaled salbutamol. None of the patients required adrenaline to resolve their reaction.
Discussion
Not all entities induced by hypersensitivity to NSAIDs fit neatly within the ENDA classification9. For example, 
patients often develop cutaneous and respiratory symptoms simultaneously5–8,10,16. By evaluating a large series of 
patients with cross-reactive hypersensitivity to NSAIDs we found such blended reactions to be the second most 
frequent reaction type after NIUA in our population, representing more than 28% of cases in this study, in agree-
ment with previous findings10.
Figure 2. Percentage of underlying rhinitis, asthma, nasosinusal polyposis and atopy in the 4 Sub-groups of 
patients developing blended reactions (Sub-group I: Skin + Rhinitis/Asthma; Sub-group II: Skin + Glottis 
oedema; Sub-group III: Skin + Rhinitis/Asthma + Glottis oedema; Sub-group IV: Gastrointestinal 
symptoms + Skin/Rhinitis/Asthma/Glottis oedema) compared to NERD and NIUA.
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The aim of this study was to characterize patients developing blended reactions and to compare them to those 
developing exclusively respiratory or cutaneous symptoms. In our population, no NECD patients experienced 
respiratory symptoms in combination with cutaneous symptoms after NSAIDs intake and no blended patients 
had underlying chronic urticaria. Therefore, we used NIUA patients to represent patients with exclusively cutane-
ous manifestations for comparisons purposes and NECD patients were not further considered.
Although it is thought that both NERD and NIUA may involve COX-1 inhibition, they are also thought to rep-
resent two distinctive phenotypes, as can be seen in the response to NPT-LASA and the release of inflammatory 
mediators19,20. In blended patients there is an overlap of clinical entities as they share the same NSAIDs-induced 
respiratory and cutaneous with NERD and NIUA, respectively. Moreover, blended patients have a similar pro-
portion of underlying rhinitis than NERD and atopy than NIUA. However, although the proportion of underly-
ing asthma and nasosinusal polyposis is higher than NIUA, is lower than NERD. Iit is unclear whether blended 
reactions represent a further phenotype or are part of a NERD-NIUA spectrum. This is especially important for 
those patients that develop throat tightness. Such tightness is considered as glottis oedema, a form of angioedema. 
As such, it should be decided whether these patients belong to the NIUA category or to NERD, as they have dif-
ficulty breathing due to upper airway involvement. Strikingly, we find that patients experiencing rhinitis and/or 
asthma accompanied with urticaria and/or angioedema have a similar clinical profile to NERD with respect to 
underlying diseases, and this is different from the profile of patients experiencing glottis oedema plus urticaria 
and/or angioedema, as well as NIUA patients. In addition, the percentage of positive responses to NPT-LASA 
in blended reactions is similar to NERD, with no significant differences between patients experiencing urticaria 
and/or angioedema accompanied by rhinitis and/or asthma and/or glottis oedema. Therefore, although patients 
with glottis oedema had a different clinical profile to NERD, appearing to be more similar to NIUA, the positive 
response to NPT-LASA allows it to be differentiated from NIUA. Previously, it has been reported that 12% of 
NIUA patients gave positive NPT-LASA19. However, these patients would be better classified as blended, as they 
reported both palpebral angioedema and glottis oedema after NSAIDs intake. Importantly, the NIUA patients in 
this study that gave negative NPT-LASA did not report glottis oedema or other respiratory symptoms in combi-
nation with skin symptoms. This has important implications for diagnosis, which we will discuss below.
We have also detected patients showing gastrointestinal plus respiratory involvement and/or skin symptoms. 
NSAIDs are known to induce alterations in the gastroduodenal tract due to direct action on the mucosa as well as pros-
taglandin synthesis. This can lead to a wide range of tissue damage from mucosal erosions to ulcus and perforation, 
inducing generally symptoms as epigastric burning and hemorrhage. The symptoms referred by our patients experi-
encing blended reactions are not related to such alterations in the gastroduodenal mucosa secondary to the action of 
NSAIDs, in our patients the gastrointestinal symptomatology is acute and includes periumbilical colic pain, vomiting 
and diarrhea, being related to the hypersensitivity induced by NSAIDs. In this sense, patients may be considered ana-
phylactic. Therefore, we suggest guidelines for NSAIDs hypersensitivity diagnoses and classification should take into 
account that cross-hypersensitivity reactions may have an anaphylactic component. Despite having a rather different 
clinical profile to NERD patients, these patients also gave a high percentage of positive response to NPT-LASA.
The high percentage of positive response to NPT-LASA in patients with blended reactions, especially in those 
that previously reported severe symptoms, is an important finding, with potentially important implications for 
diagnosis as this test is known to be safer than oral DPT20. Therefore, we suggest that NPT-LASA should be the 
first diagnostic approach in blended patients independently of the organ involved and we propose the inclusion 
of this test in the diagnostic algorithm for NSAIDs hypersensitivity reactions (Fig. 1).
Blended reactions represent a systemic clinical entity involving at least 2 organs, that can be severe and may be 
confused with SNIUAA. However, DPT with ASA can be used to differentiate between selective and cross-reactive 
hypersensitivity reactions10,21,22. This has important clinical implications, as patients with selective reactions can 
tolerate other NSAIDs9, whereas in cross-reactive hypersensitivity a safe alternative NSAID must be found.
Group
Diagnosis method n (%)
Clinical history NPT-LASA Positive DPT to ASA
Blended n = 261 41 (15.7) 201 (77) 19 (7.3)
NERD n = 108 20 (18.54) 85 (78.7) 3 (2.8)
NIUA n = 511 340 (66.5) — 172 (33.6)
p <0.0001 NS <0.0001
Table 4. Methods used to achieve diagnosis for each clinical entity.
Group
Cumulative dose ASA in 
positive DPT, median (IQR)
Interval (minutes) ASA dose-positive 
response in DPT, median (IQR)
Blended n = 261 250 (113.7–500) 60 (30–112.5)
NERD n = 108 75 (46.2–200) 60 (51.2–75)
NIUA n = 511 300 (100–500) 90 (30–165)
p 0.4002 0.6519
Table 5. Cumulative dose ASA and time interval between ASA administration and reaction in positive DPT. 
IQR: interquartile range.
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Symptoms induced by ASA or other strong COX-1 inhibitors are crucial to define the phenotype, as the 
potency with which NSAID inhibit COX-1 can influence the symptoms induced by the drug. For example, 
meloxicam or paracetamol can induce cutaneous symptoms exclusively, whilst ASA induces skin and respiratory 
symptoms in the same patient. In our population, patients tended not to vary in terms of reported symptoms 
for repeated episodes, and for most of them a strong COX-1 inhibitor was involved. Patients with positive DPT 
responses to ASA experienced similar symptoms to those recorded in their clinical history, although generally 
milder, as they were challenged in a controlled manner and responded to lower doses. Only in 14 (5.36%) patients 
there was a difference in the phenotype established by clinical history (they reported only one episode which 
manifested as skin symptoms after paracetamol, meloxicam or etoricoxib intake and no strong COX-1 inhibitor 
was taken between the reaction and the study) compared to that established by DPT (skin and respiratory symp-
toms in DTP to ASA). Therefore, the phenotypes in our population were very reproducible.
Reports have shown that dipyrone and paracetamol are relatively safe drugs as therapeutic alternatives in 
NERD patients23,24 whereas up to 30% of subjects with NIUA may also be intolerant to these drugs5,10,25,26. Here, 
we found the number of NSAIDs involved and the percentage of patients having reactions induced by dipyrone 
and paracetamol to be higher in patients with blended reactions than for NERD. It would appear that patients 
developing blended reactions to NSAIDs show varying degrees of overlap with NERD and NIUA. Nevertheless, 
we do not know if NERD patients can develop skin symptoms over time, whilst long term studies of NIUA 
patients did not show the development of respiratory symptoms in the natural course of their disease27,28. Further 
longitudinal studies alongside investigation of the underlying mechanisms may help clarify the nature of the 
relationship between the different entities. Whilst the inhibition of COX-1 is thought to participate in these reac-
tions6,29, and this has been studied in depth in NERD subjects23, additional studies are required to shed light on 
the mechanisms of NIUA and blended reactions.
Summarizing, the results of this study indicate that blended reactions are a frequently occurring, complex 
and potentially severe condition for which fewer alternative drugs may exist than for NERD, due to increased 
sensitivity to dipyrone and paracetamol. Given the frequency of these reactions, we would suggest further inves-
tigation with the aim of extending the ENDA guidelines in terms of including patients with blended reactions, 
with potential subdivisions within this category. We have also shown that NPT-LASA represents a useful diag-
nostic approach for these reactions and should be considered when dealing with a patient with blended reaction 
symptoms. Future studies should aim to clarify the pathomechanisms involved and the natural evolution of these 
reactions.
References
 1. Gomes, E. et al. Self-reported drug allergy in a general adult Portuguese population. Clin. Exp. Allergy. 34, 1597–1601 (2004).
 2. Messaad, D. et al. Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann. 
Intern. Med. 140, 1001–1006 (2004).
 3. Chalabianloo, F. et al. Clinical characteristics of patients with drug hypersensitivity in Norway: a single-centre study. 
Pharmacoepidemiology. Drug Saf. 20, 506–513 (2011).
 4. Doña, I. et al. Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. 
J. Investig. Allergol. Clin. Immunology. 22, 363–371 (2012).
 5. Quiralte, J., Blanco, C., Castillo, R., Delgado, J. & Carrillo, T. Intolerance to nonsteroidal antiinflammatory drugs: results of 
controlled drug challenges in 98 patients. J. Allergy Clin. Immunol. 98, 678–685 (1996).
 6. Stevenson, D. D., Sanchez-Borges, M. & Szczeklik, A. Classification of allergic and pseudoallergic reactions to drugs that inhibit 
cyclooxygenase enzymes. Ann. Allergy Asthma Immunol. 87, 177–180 (2001).
 7. Sanchez-Borges, M., Capriles-Behrens, E. & Caballero-Fonseca, F. Hypersensitivity to non-steroidal anti-inflammatory drugs in 
childhood. Pediatric Allergy Immunol. 15, 376–380 (2004).
 8. Caimmi, S., Caimmi, D., Bousquet, P. J. & Demoly, P. How can we better classify NSAID hypersensitivity reactions?–validation from 
a large database. Int. Arch. Allergy Immunol. 159, 306–312 (2012).
 9. Kowalski, M. L. et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal 
anti-inflammatory drugs. Allergy. 68, 1219–1232 (2013).
 10. Doña, I. et al. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of 
response. Clin. Exp. Allergy. 41, 86–95 (2011).
 11. Zambonino, M. A. et al. Drug provocation tests in the diagnosis of hypersensitivity reactions to non-steroidal anti-inflammatory 
drugs in children. Pediatric Allergy Immunol. 24, 151–159 (2013).
 12. Szczeklik, A., Gryglewski, R. J., Czerniawska-Mysik, G. & Zmuda, A. Aspirin-induced asthma. Hypersensitivity to fenoprofen and 
ibuprofen in relation to their inhibitory action on prostaglandin generation by different microsomal enzymic preparations. J. Allergy 
Clin. Immunol. 58, 10–18 (1976).
 13. Samter, M. & Beers, R. F. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann. Intern. Medicine. 68, 
975–983 (1968).
 14. Canto, M. G., Andreu, I., Fernandez, J. & Blanca, M. Selective immediate hypersensitivity reactions to NSAIDs. Curr. Opin. Allergy 
Clin. Immunol. 9, 293–297 (2009).
 15. Pichler, W. J. Delayed drug hypersensitivity reactions. Ann. Intern. Medicine. 139, 683–693 (2003).
 16. Cousin, M., Chiriac, A., Molinari, N., Demoly, P. & Caimmi, D. Phenotypical characterization of children with hypersensitivity 
reactions to NSAIDs. Pediatric Allergy Immunol. 27, 743–748 (2016).
 17. Kidon, M. I. et al. Early presentation with angioedema and urticaria in cross-reactive hypersensitivity to nonsteroidal 
antiinflammatory drugs among young, Asian, atopic children. Pediatrics. 116, e675–680 (2005).
 18. Blanca-Lopez, N. et al. Value of the clinical history in the diagnosis of urticaria/angioedema induced by NSAIDs with cross-
intolerance. Clin. Exp. Allergy. 43, 85–91 (2013).
 19. Campo, P. et al. Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity 
reactions to NSAIDs. Allergy. 68, 1001–1007 (2013).
 20. Nizankowska-Mogilnicka, E. et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. 
Allergy. 62, 1111–1118 (2007).
 21. Blanca-Lopez, N. et al. ASA must be given to classify multiple NSAID-hypersensitivity patients as selective or cross-intolerant. 
Allergy. 71, 576–578 (2016).
 22. Asero, R. Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs. Clin. Exp. 
Allergy. 35, 713–716 (2005).
www.nature.com/scientificreports/
9SCIEnTIfIC RePoRTS |         (2018) 8:16710  | DOI:10.1038/s41598-018-34668-1
 23. Stevenson, D. D. & Szczeklik, A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J. Allergy Clin. Immunol. 
118, 773–786 (2006).
 24. Szczeklik, A. & Stevenson, D. D. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J. Allergy Clin. 
Immunol. 111, 913–21 (2003).
 25. Doña, I. et al. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-
inflammatory drugs. Allergy. 66, 1428–1433 (2011).
 26. Asero, R. Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders. Ann. Allergy 
Asthma Immunol. 82, 554–558 (1999).
 27. Doña, I. et al. Natural evolution in patients with nonsteroidal anti-inflammatory drug-induced urticaria/angioedema. Allergy. 72, 
1346–1355 (2017).
 28. Doña, I. et al. NSAID-induced urticaria/angioedema does not evolve into chronic urticaria: a 12-year follow-up study. Allergy. 69, 
438–444 (2014).
 29. Sanchez-Borges, M. NSAID hypersensitivity (respiratory, cutaneous, and generalized anaphylactic symptoms). Med. Clin. North 
Am. 94, 853–864 (2010).
Acknowledgements
JR Perkins also contributed to the English version. We would like to thank the nurses from our Allergy Unit for 
performing SPT, NPT-LASA and DPT. The present study has been supported by the Andalusian Government (PI-
0463-2013), Institute of Health Carlos III of the Ministry of Economy and Competitiveness (grants cofounded 
by European Regional Development Fund (ERDF): RETIC ARADyAL RD16/0006/0001 and PI17/1253) and 
the Spanish Society of Allergology (Fondo de Investigación de la Fundación de la SEAIC 2016). I Doña holds a 
Juan Rodes research contract (JR15/00036), G Bogas holds a Rio Hortega contract (CM16/0067), JA Cornejo-
García received funding from the Miguel Servet Program (Ref CP14/00034), and JR Perkins from the Sara 
Borrell Program (Ref CD14/00242), all of them from the Carlos III National Health Institute, Spanish Ministry of 
Economy and Competitiveness (grants cofounded by European Social Fund, ESF).
Author Contributions
I. Doña and M.J. Torres contributed to study design. I. Doña, E. Barrionuevo, M. Salas, G. Bogas and M.J. Torres 
recruited patients and performed the clinical evaluations. I. Doña, J.J. Laguna, Agúndez J., García-Martín E, 
J.A. Cornejo-García, J.R. Perkins and M.J. Torres wrote the manuscript. I. Doña and J.R. Perkins prepared 
illustrations.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-34668-1.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
